JP2006516570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516570A5 JP2006516570A5 JP2006500939A JP2006500939A JP2006516570A5 JP 2006516570 A5 JP2006516570 A5 JP 2006516570A5 JP 2006500939 A JP2006500939 A JP 2006500939A JP 2006500939 A JP2006500939 A JP 2006500939A JP 2006516570 A5 JP2006516570 A5 JP 2006516570A5
- Authority
- JP
- Japan
- Prior art keywords
- emtricitabine
- tenofovir disoproxil
- disoproxil fumarate
- pharmaceutical formulation
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 23
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 22
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 21
- 229960000366 emtricitabine Drugs 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000009472 formulation Methods 0.000 claims 9
- 239000011248 coating agent Substances 0.000 claims 8
- 238000000576 coating method Methods 0.000 claims 8
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 7
- 239000002552 dosage form Substances 0.000 claims 7
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 229920002472 Starch Polymers 0.000 claims 5
- 235000019698 starch Nutrition 0.000 claims 5
- 239000008107 starch Substances 0.000 claims 5
- 239000003826 tablet Substances 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 4
- -1 ester fumarate Chemical class 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 229940054565 sustiva Drugs 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- SGOIRFVFHAKUTI-UHFFFAOYSA-N 1-(6-aminopurin-9-yl)propan-2-yloxymethylphosphonic acid Chemical compound N1=CN=C2N(CC(C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-UHFFFAOYSA-N 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical group N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000036436 anti-hiv Effects 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229940112586 kaletra Drugs 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 3
- 229940107904 reyataz Drugs 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 2
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- YFUCIEVRSCGPFH-UHFFFAOYSA-N 1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound C1SC(CO)OC1N1C(=O)N=CC=C1 YFUCIEVRSCGPFH-UHFFFAOYSA-N 0.000 claims 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229910000503 Na-aluminosilicate Inorganic materials 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- 239000000378 calcium silicate Substances 0.000 claims 1
- 229910052918 calcium silicate Inorganic materials 0.000 claims 1
- 235000012241 calcium silicate Nutrition 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical group [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims 1
- 239000000395 magnesium oxide Substances 0.000 claims 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 229920003124 powdered cellulose Polymers 0.000 claims 1
- 235000019814 powdered cellulose Nutrition 0.000 claims 1
- MKFWBVKQDGNXDW-SPIKMXEPSA-N proglumetacin dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1C(=O)NC(C(=O)N(CCC)CCC)CCC(=O)OCCCN(CC1)CCN1CCOC(=O)CC(C1=CC(OC)=CC=C11)=C(C)N1C(=O)C1=CC=C(Cl)C=C1 MKFWBVKQDGNXDW-SPIKMXEPSA-N 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000000429 sodium aluminium silicate Substances 0.000 claims 1
- 235000012217 sodium aluminium silicate Nutrition 0.000 claims 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44024603P | 2003-01-14 | 2003-01-14 | |
| US44030803P | 2003-01-14 | 2003-01-14 | |
| US60/440,308 | 2003-01-14 | ||
| US60/440246 | 2003-01-14 | ||
| PCT/US2004/000832 WO2004064845A1 (en) | 2003-01-14 | 2004-01-13 | Compositions and methods for combination antiviral therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010030680A Division JP2010120957A (ja) | 2003-01-14 | 2010-02-15 | 組み合わせ抗ウイルス治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516570A JP2006516570A (ja) | 2006-07-06 |
| JP2006516570A5 true JP2006516570A5 (enExample) | 2006-08-17 |
| JP4996241B2 JP4996241B2 (ja) | 2012-08-08 |
Family
ID=32776014
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500939A Expired - Lifetime JP4996241B2 (ja) | 2003-01-14 | 2004-01-13 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2006500943A Pending JP2006515624A (ja) | 2003-01-14 | 2004-01-13 | 組み合わせ抗ウイルス療法のための組成物および方法 |
| JP2010030680A Withdrawn JP2010120957A (ja) | 2003-01-14 | 2010-02-15 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2013221825A Withdrawn JP2014037430A (ja) | 2003-01-14 | 2013-10-25 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2015034888A Withdrawn JP2015098488A (ja) | 2003-01-14 | 2015-02-25 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2017000869A Withdrawn JP2017057232A (ja) | 2003-01-14 | 2017-01-06 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2018226434A Withdrawn JP2019052174A (ja) | 2003-01-14 | 2018-12-03 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2020174621A Pending JP2021004264A (ja) | 2003-01-14 | 2020-10-16 | 組み合わせ抗ウイルス治療のための組成物および方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500943A Pending JP2006515624A (ja) | 2003-01-14 | 2004-01-13 | 組み合わせ抗ウイルス療法のための組成物および方法 |
| JP2010030680A Withdrawn JP2010120957A (ja) | 2003-01-14 | 2010-02-15 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2013221825A Withdrawn JP2014037430A (ja) | 2003-01-14 | 2013-10-25 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2015034888A Withdrawn JP2015098488A (ja) | 2003-01-14 | 2015-02-25 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2017000869A Withdrawn JP2017057232A (ja) | 2003-01-14 | 2017-01-06 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2018226434A Withdrawn JP2019052174A (ja) | 2003-01-14 | 2018-12-03 | 組み合わせ抗ウイルス治療のための組成物および方法 |
| JP2020174621A Pending JP2021004264A (ja) | 2003-01-14 | 2020-10-16 | 組み合わせ抗ウイルス治療のための組成物および方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (11) | US20040224916A1 (enExample) |
| EP (4) | EP1583542B9 (enExample) |
| JP (8) | JP4996241B2 (enExample) |
| KR (3) | KR20090053867A (enExample) |
| CN (2) | CN105596356A (enExample) |
| AP (1) | AP2089A (enExample) |
| AT (1) | ATE398455T1 (enExample) |
| AU (3) | AU2004206821C1 (enExample) |
| BR (1) | BRPI0406760A (enExample) |
| CA (2) | CA2512475C (enExample) |
| CY (1) | CY1108355T1 (enExample) |
| DE (1) | DE602004014470D1 (enExample) |
| DK (1) | DK1583542T3 (enExample) |
| EA (2) | EA201100293A1 (enExample) |
| ES (1) | ES2308136T3 (enExample) |
| HR (2) | HRP20050619A2 (enExample) |
| IL (1) | IL169243A (enExample) |
| IS (1) | IS7977A (enExample) |
| MX (1) | MXPA05007016A (enExample) |
| NO (3) | NO337917B1 (enExample) |
| NZ (1) | NZ540728A (enExample) |
| PL (2) | PL378368A1 (enExample) |
| PT (1) | PT1583542E (enExample) |
| SI (1) | SI1583542T1 (enExample) |
| WO (2) | WO2004064846A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4996241B2 (ja) | 2003-01-14 | 2012-08-08 | ギリアード サイエンシーズ， インコーポレイテッド | 組み合わせ抗ウイルス治療のための組成物および方法 |
| ES2727577T5 (en) | 2004-12-03 | 2025-04-02 | Merck Sharp & Dohme Llc | Pharmaceutical composition containing an anti-nucleating agent |
| WO2006110655A2 (en) * | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| US20070003608A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| US7827042B2 (en) | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| US8340944B2 (en) | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US8068991B2 (en) | 2005-11-30 | 2011-11-29 | The Invention Science Fund I, Llc | Systems and methods for transmitting pathogen related information and responding |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US7927787B2 (en) | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| ATE474560T1 (de) * | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| US9044509B2 (en) | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
| AR061838A1 (es) | 2006-07-07 | 2008-09-24 | Gilead Sciences Inc | Moduladores de propiedades farmacocineticas de terapeuticos |
| RU2470846C2 (ru) * | 2007-01-20 | 2012-12-27 | Мерк Патент Гмбх | Повторно закрываемый контейнер для упаковки мягких капсул |
| WO2008096369A2 (en) * | 2007-02-05 | 2008-08-14 | Matrix Laboratories Limited | Pharmaceutical formulation for use in hiv therapy |
| WO2008100848A2 (en) * | 2007-02-12 | 2008-08-21 | Board Of Regents, The University Of Texas System | Novel agent for in vivo pet imaging of tumor proliferation |
| EP2118082B1 (en) | 2007-02-23 | 2014-10-01 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
| SG185257A1 (en) * | 2007-10-10 | 2012-11-29 | Avantor Performance Mat Inc | Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof |
| EP2240604B1 (en) | 2008-01-18 | 2012-07-25 | North Carolina State University | Peptides and methods of use as therapeutics and screening agents |
| CN105055432A (zh) | 2008-01-25 | 2015-11-18 | 奇默里克斯公司 | 治疗病毒感染的方法 |
| US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
| AP3089A (en) | 2008-05-02 | 2015-01-31 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| BRPI1008664A2 (pt) | 2009-02-06 | 2016-03-08 | Gilead Sciences Inc | comprimidos para a terapia de combinação |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| EA032868B1 (ru) * | 2010-01-27 | 2019-07-31 | Вайв Хелткер Компани | Комбинация для лечения вич-инфекции |
| ES2629165T3 (es) | 2010-02-12 | 2017-08-07 | Chimerix, Inc. | Métodos de tratamiento de una infección vírica |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| JP5872539B2 (ja) | 2010-03-31 | 2016-03-01 | ギリアド ファーマセット エルエルシー | プリンヌクレオシドホスホルアミダート |
| WO2011123668A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Stereoselective synthesis of phosphorus containing actives |
| CA2797601A1 (en) | 2010-04-26 | 2011-11-10 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
| EP2389929A1 (en) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of tenofovir |
| CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| KR20130095735A (ko) * | 2010-08-01 | 2013-08-28 | 쟝수 치아타이 티안큉 파마수티컬 주식회사 | 테노포비어 디소프록실 푸마레이트의 결정 |
| EA201691695A1 (ru) * | 2010-11-19 | 2017-11-30 | Джилид Сайэнс, Инк. | Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат |
| EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
| WO2012154698A2 (en) * | 2011-05-06 | 2012-11-15 | Mckenna Charles E | Method to improve antiviral activity of nucleotide analogue drugs |
| US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| DK2794624T3 (da) | 2011-12-22 | 2019-07-22 | Geron Corp | Guanin-analoger som telomerase-substrater og påvirkere af telomer-længde |
| BR112014018918A8 (pt) | 2012-02-03 | 2017-07-11 | Gilead Sciences Inc | Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais |
| WO2013115916A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
| CN103665043B (zh) * | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| CA2889903C (en) * | 2012-10-29 | 2021-03-09 | Manjinder Singh Phull | Antiviral phosphonate analogues and process for preparation thereof |
| MX344879B (es) * | 2012-12-21 | 2017-01-11 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| CN103127028A (zh) * | 2013-03-14 | 2013-06-05 | 南京恒道医药科技有限公司 | 一种含有富马酸替诺福韦二吡呋酯的胶囊剂 |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| LT3019503T (lt) | 2013-07-12 | 2017-11-27 | Gilead Sciences, Inc. | Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui |
| WO2015028875A2 (en) * | 2013-08-29 | 2015-03-05 | Teva Pharmaceuticals Industries Ltd. | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| TW201622731A (zh) | 2014-04-08 | 2016-07-01 | 泰瓦藥品工業有限公司 | 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑 |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| CN105399771B (zh) * | 2014-07-21 | 2020-11-24 | 江苏豪森药业集团有限公司 | 替诺福韦前药晶型及其制备方法和用途 |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| LT3236972T (lt) | 2014-12-26 | 2021-11-10 | Emory University | Antivirusiniai n4-hidroksicitidino dariniai |
| JP2018509400A (ja) * | 2015-03-27 | 2018-04-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | セムブラギリンを含む医薬製剤 |
| CA2980362C (en) | 2015-04-02 | 2020-02-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| EP4070787B1 (en) * | 2015-06-30 | 2023-03-01 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| TWI620754B (zh) * | 2015-08-26 | 2018-04-11 | Method for preparing amino phosphate derivative and preparation method thereof | |
| KR102606625B1 (ko) | 2015-11-09 | 2023-11-27 | 길리애드 사이언시즈, 인코포레이티드 | 인간 면역결핍 바이러스의 치료를 위한 치료 조성물 |
| US10450335B2 (en) | 2015-12-15 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3503895B1 (en) | 2016-08-25 | 2021-09-15 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| WO2018080903A1 (en) | 2016-10-26 | 2018-05-03 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
| TR201617448A2 (tr) * | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| AU2017378893A1 (en) | 2016-12-22 | 2019-05-16 | Idenix Pharmaceuticals Llc | Antiviral benzyl-amine phosphodiamide compounds |
| CN106749254B (zh) * | 2017-01-10 | 2018-05-25 | 青岛科技大学 | 一种6-氨基嘌呤乙基萘乙酸酯类化合物及其作为植物生长调节剂的用途 |
| WO2018153977A1 (en) * | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
| GB201705087D0 (en) * | 2017-03-30 | 2017-05-17 | Univ Liverpool | Method for producing a liquid composition |
| EP3612226A1 (en) * | 2017-04-18 | 2020-02-26 | Cipla Limited | Combination therapy for use in treating retroviral infections |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| RU2662160C9 (ru) | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| KR102077060B1 (ko) * | 2017-07-14 | 2020-02-13 | 주식회사 종근당 | 테노포비어 디소프록실 아스파르트산 염을 포함하는 약제학적 조성물 |
| RU2666727C1 (ru) * | 2017-07-18 | 2018-09-12 | Андрей Александрович Иващенко | Ингибитор вируса гепатита В (ВГВ) |
| TR201713954A2 (tr) | 2017-09-20 | 2019-04-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari |
| LT3706762T (lt) | 2017-12-07 | 2024-12-27 | Emory University | N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai |
| EP3823629B1 (en) | 2018-07-19 | 2024-12-25 | Merck Sharp & Dohme LLC | Phosphinic amide prodrugs of tenofovir |
| RU2726210C2 (ru) * | 2018-12-27 | 2020-07-09 | Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" | Комбинация противовирусных средств, набор и способ лечения на ее основе |
| CN110261631A (zh) * | 2019-07-26 | 2019-09-20 | 重庆德方信息技术有限公司 | 用于健康检测装置的滴液机构 |
| CN110251476B (zh) * | 2019-08-01 | 2022-08-09 | 海思科制药(眉山)有限公司 | 一种恩曲他滨替诺福韦药物组合物 |
| WO2022089600A1 (zh) * | 2020-10-30 | 2022-05-05 | 杭州拉林智能科技有限公司 | 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用 |
| GB202407194D0 (enExample) * | 2024-05-21 | 2024-07-03 | Zentiva Ks |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US568164A (en) | 1896-09-22 | Motor attachment for bicycles | ||
| CH389608A (de) | 1960-01-19 | 1965-03-31 | Sandoz Ag | Verfahren zur Herstellung von neuen Äthern |
| US3524846A (en) | 1967-06-02 | 1970-08-18 | Syntex Corp | Process for the didealkylation of phosphonate esters |
| US3622677A (en) | 1969-07-07 | 1971-11-23 | Staley Mfg Co A E | Compressed tablets containing compacted starch as binder-disintegrant ingredient |
| CH531000A (de) | 1970-03-11 | 1972-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer Benzocycloheptathiophene |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| US4003878A (en) | 1972-12-07 | 1977-01-18 | Avtex Fibers Inc. | Method of preparing an alkali-metal salt of an alkoxysulfonated benzoic acid glycol ester |
| GB1523865A (en) | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| DE2645710C2 (de) | 1976-10-09 | 1985-06-27 | Merck Patent Gmbh, 6100 Darmstadt | Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung |
| US4384005A (en) | 1980-09-26 | 1983-05-17 | General Foods Corporation | Non-friable, readily-soluble, compressed tablets and process for preparing same |
| GB2111043B (en) | 1980-12-12 | 1985-02-06 | Ciba Geigy Ag | Novel cephalosporin esters |
| US4355032B2 (en) | 1981-05-21 | 1990-10-30 | 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent | |
| JPS5879983A (ja) | 1981-11-06 | 1983-05-13 | Kanebo Ltd | 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物 |
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4476248A (en) | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
| EP0141927B1 (en) | 1983-08-18 | 1991-10-30 | Beecham Group Plc | Antiviral guanine derivatives |
| US5155268A (en) | 1984-05-04 | 1992-10-13 | The Upjohn Company | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides |
| EP0182024B1 (en) | 1984-09-20 | 1991-04-03 | Beecham Group Plc | Purine derivatives and their pharmaceutical use |
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| IL84477A (en) | 1986-11-18 | 1995-12-08 | Bristol Myers Squibb Co | History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them |
| EP0309491A1 (en) | 1987-01-20 | 1989-04-05 | Sri International | Antiviral agents |
| GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| ZA885709B (en) | 1987-08-19 | 1989-04-26 | Fujisawa Pharmaceutical Co | Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer) |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US6175008B1 (en) | 1988-04-11 | 2001-01-16 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| US5466806A (en) | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| US5453503A (en) | 1988-10-11 | 1995-09-26 | Eli Lilly And Company | Azetidinone intermediates to carbacephalosporins and process |
| CA2001715C (en) | 1988-11-14 | 1999-12-28 | Muzammil M. Mansuri | Carbocyclic nucleosides and nucleotides |
| UA45942A (uk) * | 1989-02-08 | 2002-05-15 | Біокем Фарма, Інк. | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція |
| US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5827727A (en) | 1990-02-01 | 1998-10-27 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| GB9009861D0 (en) * | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| JP3347723B2 (ja) | 1990-06-13 | 2002-11-20 | グラツィエル，アーノルド | 含リンプロドラッグ |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| EP0539487A1 (en) | 1990-07-19 | 1993-05-05 | Beecham Group Plc | Antiviral phosphono-alken derivatives of purines |
| ES2149157T3 (es) | 1990-08-10 | 2000-11-01 | Acad Of Science Czech Republic | Nuevo procedimiento para la preparacion de nucleotidos. |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| CA2054126A1 (en) | 1990-10-26 | 1992-04-27 | Michiyuki Sendai | Cephem compounds, their production and use |
| US5587480A (en) * | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
| US5208221A (en) | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
| GB9026164D0 (en) | 1990-12-01 | 1991-01-16 | Beecham Group Plc | Pharmaceuticals |
| US5179104A (en) | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| IL100965A (en) | 1991-02-22 | 1999-12-31 | Univ Emory | 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it |
| US6812233B1 (en) | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
| DE69206876T3 (de) * | 1991-05-16 | 2004-08-12 | Glaxo Group Ltd., Greenford | Nukleosidanalogen enthaltende Antiviren-Zubereitungen |
| GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
| ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| GB9116601D0 (en) | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
| US6177435B1 (en) * | 1992-05-13 | 2001-01-23 | Glaxo Wellcome Inc. | Therapeutic combinations |
| JP2721434B2 (ja) | 1992-06-23 | 1998-03-04 | 山之内製薬株式会社 | ヘテロ環ビス（フォスフォン酸）誘導体１水和物の新規結晶 |
| US5532225A (en) | 1992-07-31 | 1996-07-02 | Sri International | Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods |
| US5432172A (en) | 1992-08-03 | 1995-07-11 | The Research Foundation Of State University Of New York | Biological applications of alkaloids derived from the tunicate Eudistoma sp. |
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5665720A (en) | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| CA2107644A1 (en) | 1992-10-28 | 1994-04-29 | David R. Magnin | .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd |
| CA2154681A1 (en) | 1993-02-03 | 1994-08-18 | Mark David Erion | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
| US5514798A (en) | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
| GB9311709D0 (en) | 1993-06-07 | 1993-07-21 | Iaf Biochem Int | Stereoselective synthesis of nucleoside analogues using bicycle intermediate |
| DE69426904T2 (de) | 1993-06-29 | 2001-10-11 | Mitsubishi Chemical Corp., Tokio/Tokyo | Phosphonat-Nukleotid Ester-Derivate |
| CA2171868A1 (en) | 1993-09-17 | 1995-03-23 | Petr Alexander | Method for dosing therapeutic compounds |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| CA2171743C (en) | 1993-09-17 | 2007-11-20 | Norbert W. Bischofberger | Nucleotide analogs |
| WO1995032957A1 (en) | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles |
| US5514557A (en) | 1994-06-06 | 1996-05-07 | Genetic Testing Institute Inc. | Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins |
| PE32296A1 (es) | 1994-07-28 | 1996-08-07 | Hoffmann La Roche | Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables |
| US5512596A (en) | 1994-09-02 | 1996-04-30 | Gilead Sciences, Inc. | Aromatic compounds |
| US5486806A (en) * | 1994-11-09 | 1996-01-23 | Firari; Harold A. | Anti-hijacking and theft prevention device for motor vehicles |
| US5684018A (en) | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| US5618964A (en) | 1995-06-07 | 1997-04-08 | Bristol-Myers Squibb Company | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method |
| CA2224008C (en) * | 1995-06-07 | 2009-08-18 | Trimeris, Inc. | The treatment of hiv and other viral infections using combinatorial therapy |
| CA2261619C (en) | 1996-07-26 | 2006-05-23 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5733788A (en) | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| AU4428397A (en) | 1996-09-20 | 1998-04-14 | Warner-Lambert Company | Oral compositions containing a zinc compound |
| GB9622681D0 (en) | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
| US6113920A (en) * | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
| US5965729A (en) | 1997-02-05 | 1999-10-12 | Merck & Co., Inc. | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
| US6143877A (en) | 1997-04-30 | 2000-11-07 | Epoch Pharmaceuticals, Inc. | Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids |
| CN1900090A (zh) * | 1997-07-25 | 2007-01-24 | 吉尔利德科学股份有限公司 | 核苷酸类似物组合物 |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| US6270957B1 (en) * | 1997-08-26 | 2001-08-07 | Wisconsin Alumni Research Foundation | Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection |
| CO4970782A1 (es) * | 1997-11-13 | 2000-11-07 | Merck & Co Inc | Terapia combinada para el tratamiento del sida |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6127121A (en) | 1998-04-03 | 2000-10-03 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination |
| UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| EP1332757B1 (en) | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
| CO5070643A1 (es) | 1998-05-27 | 2001-08-28 | Merck & Co Inc | Formulacion en tabletas comprimidas |
| AU4716299A (en) | 1998-06-24 | 2000-01-10 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
| RU2244712C2 (ru) * | 1998-08-12 | 2005-01-20 | Гайлид Сайенсиз, Инк. | Способ получения 1,3-оксатиоланового нуклеозида, способ получения производного 1,3-оксатиоланил-5-она |
| GB9820420D0 (en) | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| EP1124562B1 (en) * | 1998-11-02 | 2005-01-19 | Gilead Sciences, Inc. | Combination therapy to treat hepatitis b virus |
| GB9909154D0 (en) | 1999-04-22 | 1999-06-16 | Nippon Glaxo Limited | Pharmaceutical formulation |
| US6660845B1 (en) | 1999-11-23 | 2003-12-09 | Epoch Biosciences, Inc. | Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
| DE60114772T2 (de) | 2000-02-02 | 2006-07-20 | Dorian Bevec | Aromatisches guanylhydrazon zur behandlung resistenter viraler infektionen |
| HRP20020649A2 (en) * | 2000-02-29 | 2004-12-31 | Bristol Myers Squibb Co | Low dose entecavir formulation and use |
| AU2001282941C1 (en) | 2000-07-21 | 2016-12-22 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| IL156447A0 (en) | 2000-12-15 | 2004-01-04 | Triangle Pharmaceuticals Inc | Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors |
| US6900315B2 (en) | 2001-02-06 | 2005-05-31 | Yale University | 2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms |
| DK1574512T3 (da) | 2001-03-01 | 2008-03-03 | Abbott Lab | Polymorfe og andre krystallinske former af cis-FTC |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| AU2002359518A1 (en) | 2001-11-27 | 2003-06-10 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| AU2002242676B2 (en) | 2002-01-16 | 2008-05-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| EP1525216A4 (en) * | 2002-01-24 | 2009-07-08 | Sangstat Medical Corp | COMBINATION THERAPY FOR THE TREATMENT OF HIV INFECTION |
| EA008775B1 (ru) | 2002-04-26 | 2007-08-31 | Джилид Сайэнс, Инк. | Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция |
| MXPA05003637A (es) | 2002-12-09 | 2005-08-16 | Univ Georgia Res Found | Dioxolan timina y combinaciones para utilizarse contra cepas de vih resistentes. |
| EP1575566B1 (en) | 2002-12-26 | 2012-02-22 | Pozen, Inc. | Multilayer dosage forms containing naproxen and triptans |
| JP4996241B2 (ja) | 2003-01-14 | 2012-08-08 | ギリアード サイエンシーズ， インコーポレイテッド | 組み合わせ抗ウイルス治療のための組成物および方法 |
| US8263126B2 (en) | 2003-06-06 | 2012-09-11 | Ethypharm | Orally-dispersible multilayer tablet |
| WO2006078783A2 (en) | 2005-01-18 | 2006-07-27 | Chaker, Adra N. | Htm4 used for cell-cycle regulation through its interaction with kap |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| EP1899332A1 (en) | 2005-06-24 | 2008-03-19 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
| EP1910573B1 (en) * | 2005-07-22 | 2013-09-04 | CytoDyn, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| US7448494B2 (en) * | 2005-08-10 | 2008-11-11 | Certain Teed Corporation | Loose fill insulation packaged with additive |
| ATE474560T1 (de) | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| GB0525898D0 (en) | 2005-12-20 | 2006-02-01 | Pharmo Bioscience As | Screening compounds for activity in modulating chloride ion transport |
| JP2010515771A (ja) | 2007-01-16 | 2010-05-13 | プロテオロジクス リミテッド | トポイソメラーゼインヒビターの治療効果を増強する方法 |
| US20110275679A1 (en) | 2008-08-06 | 2011-11-10 | Bionevia Pharmaceuticals, Inc. | Flupirtine hydrochloride maleic acid cocrystal |
| WO2012003413A1 (en) | 2010-06-30 | 2012-01-05 | The Broad Institute, Inc. | Novel solid forms of tacedinaline |
| EA201691695A1 (ru) | 2010-11-19 | 2017-11-30 | Джилид Сайэнс, Инк. | Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат |
-
2004
- 2004-01-13 JP JP2006500939A patent/JP4996241B2/ja not_active Expired - Lifetime
- 2004-01-13 HR HR20050619A patent/HRP20050619A2/hr not_active Application Discontinuation
- 2004-01-13 CN CN201510697340.9A patent/CN105596356A/zh active Pending
- 2004-01-13 JP JP2006500943A patent/JP2006515624A/ja active Pending
- 2004-01-13 EP EP20040701819 patent/EP1583542B9/en not_active Revoked
- 2004-01-13 WO PCT/US2004/000868 patent/WO2004064846A1/en not_active Ceased
- 2004-01-13 US US10/757,122 patent/US20040224916A1/en not_active Abandoned
- 2004-01-13 AP AP2005003348A patent/AP2089A/en active
- 2004-01-13 US US10/540,794 patent/US20060246130A1/en not_active Abandoned
- 2004-01-13 DE DE200460014470 patent/DE602004014470D1/de not_active Expired - Lifetime
- 2004-01-13 WO PCT/US2004/000832 patent/WO2004064845A1/en not_active Ceased
- 2004-01-13 NZ NZ540728A patent/NZ540728A/en not_active IP Right Cessation
- 2004-01-13 US US10/757,141 patent/US20040224917A1/en not_active Abandoned
- 2004-01-13 EA EA201100293A patent/EA201100293A1/ru unknown
- 2004-01-13 SI SI200430842T patent/SI1583542T1/sl unknown
- 2004-01-13 KR KR1020097009376A patent/KR20090053867A/ko not_active Ceased
- 2004-01-13 KR KR20057013069A patent/KR100860136B1/ko not_active Expired - Lifetime
- 2004-01-13 MX MXPA05007016A patent/MXPA05007016A/es active IP Right Grant
- 2004-01-13 PL PL37836804A patent/PL378368A1/pl unknown
- 2004-01-13 DK DK04701819T patent/DK1583542T3/da active
- 2004-01-13 AU AU2004206821A patent/AU2004206821C1/en not_active Expired
- 2004-01-13 HR HRP20140379AA patent/HRP20140379A2/hr not_active Application Discontinuation
- 2004-01-13 CN CN201210094391.9A patent/CN102670629B/zh not_active Expired - Lifetime
- 2004-01-13 PT PT04701819T patent/PT1583542E/pt unknown
- 2004-01-13 ES ES04701819T patent/ES2308136T3/es not_active Expired - Lifetime
- 2004-01-13 KR KR1020087007002A patent/KR20080032014A/ko not_active Ceased
- 2004-01-13 EP EP15190214.5A patent/EP3025718A1/en not_active Withdrawn
- 2004-01-13 AT AT04701819T patent/ATE398455T1/de active
- 2004-01-13 EP EP20080152527 patent/EP1923063A3/en not_active Ceased
- 2004-01-13 BR BRPI0406760 patent/BRPI0406760A/pt not_active Application Discontinuation
- 2004-01-13 EA EA200501134A patent/EA015145B1/ru not_active IP Right Cessation
- 2004-01-13 CA CA 2512475 patent/CA2512475C/en not_active Expired - Lifetime
- 2004-01-13 CA CA 2512319 patent/CA2512319A1/en not_active Abandoned
- 2004-01-13 EP EP20040701840 patent/EP1585527A1/en not_active Ceased
- 2004-01-13 AU AU2004206827A patent/AU2004206827A1/en not_active Abandoned
- 2004-01-13 US US10/540,782 patent/US20060234982A1/en not_active Abandoned
- 2004-01-13 PL PL40825404A patent/PL408254A1/pl unknown
-
2005
- 2005-06-16 IL IL169243A patent/IL169243A/en active IP Right Grant
- 2005-08-12 IS IS7977A patent/IS7977A/is unknown
- 2005-08-12 NO NO20053817A patent/NO337917B1/no not_active IP Right Cessation
-
2008
- 2008-08-20 US US12/195,161 patent/US8592397B2/en not_active Expired - Fee Related
- 2008-09-04 US US12/204,174 patent/US8716264B2/en not_active Expired - Lifetime
- 2008-09-17 CY CY081101015T patent/CY1108355T1/el unknown
-
2009
- 2009-02-04 AU AU2009200414A patent/AU2009200414B2/en not_active Expired
-
2010
- 2010-02-15 JP JP2010030680A patent/JP2010120957A/ja not_active Withdrawn
-
2013
- 2013-10-25 JP JP2013221825A patent/JP2014037430A/ja not_active Withdrawn
-
2014
- 2014-03-27 US US14/227,653 patent/US20140213556A1/en not_active Abandoned
- 2014-10-24 US US14/523,758 patent/US9457036B2/en not_active Expired - Fee Related
- 2014-10-24 US US14/523,783 patent/US9744181B2/en not_active Expired - Fee Related
-
2015
- 2015-02-25 JP JP2015034888A patent/JP2015098488A/ja not_active Withdrawn
- 2015-05-22 NO NO20150656A patent/NO340951B1/no not_active IP Right Cessation
-
2017
- 2017-01-06 JP JP2017000869A patent/JP2017057232A/ja not_active Withdrawn
- 2017-05-04 US US15/586,500 patent/US20170232019A1/en not_active Abandoned
- 2017-06-14 US US15/622,484 patent/US20170273994A1/en not_active Abandoned
- 2017-07-17 NO NO20171193A patent/NO20171193A1/no not_active Application Discontinuation
-
2018
- 2018-12-03 JP JP2018226434A patent/JP2019052174A/ja not_active Withdrawn
-
2020
- 2020-10-16 JP JP2020174621A patent/JP2021004264A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516570A5 (enExample) | ||
| AU2013336491B2 (en) | Pharmaceutical antiretroviral composition | |
| ES2543108T3 (es) | Preparación sólida fácilmente administrable | |
| EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
| WO2014184553A1 (en) | Pharmaceutical antiretroviral compositions | |
| RU2012121857A (ru) | Твердые фармацевтические композиции, содержащие ингибитор интегразы | |
| EP2822560A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
| CA2633603A1 (en) | Pharmaceutical combination | |
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| US20160199396A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
| ES2910924T3 (es) | Composiciones farmacéuticas orales sólidas que comprenden tenofovir y emtricitabina | |
| AU2012264475A1 (en) | Pharmaceutical antiretroviral composition | |
| ES2286471T3 (es) | Composiciones farmaceuticas antivirales. | |
| JP4812626B2 (ja) | 口腔内溶解用固形製剤 | |
| CA2703918C (en) | Solid pharmaceutical dosage forms of atazanavir and ritonavir combinations | |
| JP2021075529A (ja) | 医薬組成物 | |
| WO2009037449A1 (en) | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors | |
| WO2021091498A1 (en) | Pharmaceutical compositions comprising tenofovir and emtricitabine | |
| EP3334419A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| WO2019145926A1 (en) | Stable thiamine containing pharmaceutical formulations | |
| JP2006206465A (ja) | 持続性口腔内溶解用固形製剤 | |
| EP2797583B1 (en) | Combined pharmaceutical formulation containing diacerein | |
| TR2022007368A2 (tr) | Anti̇vi̇ral kompozi̇syonlar | |
| TR2022007384A2 (tr) | Anti̇vi̇ral etken madde i̇hti̇va eden kati dozaj formlari | |
| JP2021075528A (ja) | 医薬組成物 |